Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial

INTRODUCTION: Finding the optimal management strategy for patients with advanced, metastatic neuroendocrine tumours (NETs) of the gastrointestinal tract and pancreas is a work in progress. Sunitinib and everolimus are currently approved for the treatment of progressive, unresectable, locally advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Neychev, Vladimir, Steinberg, Seth M, Cottle-Delisle, Candice, Merkel, Roxanne, Nilubol, Naris, Yao, Jianhua, Meltzer, Paul, Pacak, Karel, Marx, Stephen, Kebebew, Electron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442235/
https://www.ncbi.nlm.nih.gov/pubmed/25991462
http://dx.doi.org/10.1136/bmjopen-2015-008248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442235/
https://www.ncbi.nlm.nih.gov/pubmed/25991462
http://dx.doi.org/10.1136/bmjopen-2015-008248

Ejemplares similares